Document:

EX-10.1

EMPLOYMENT AGREEMENT

This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of January 21, 2014
(the “Effective Date”) by and between Mark A. Olson (“Employee”) and CommScope,
Inc., a Delaware corporation (the “Company”).

WITNESSETH:

WHEREAS, Employee is currently employed by the Company;

WHEREAS, Employee is currently a party to that certain Severance Protection Agreement dated
November 15, 2009 with the Company (the “Severance Agreement”);

WHEREAS, the Company and Employee wish to continue the employment of Employee by the Company,
but on the terms and conditions set forth in this Agreement;

WHEREAS, the Company and Employee wish to terminate the Severance Agreement and provide
severance and other benefits to Employee on the terms and conditions set forth in this Agreement;

NOW, THEREFORE, in consideration of the mutual promises and covenants herein contained, the
parties hereto agree as follows:

1. Employment. Subject to the provisions of Section 6, the Company hereby employs
Employee and Employee accepts such employment upon the terms and conditions hereinafter set forth
(the “Employment”).

2. Term of Employment.  Subject to the provisions of Section 6, the term of Employee’s
employment pursuant to this Agreement shall commence on the Effective Date and shall terminate on
December 31, 2014 (such period, the “Term”).  Notwithstanding the foregoing, the Term shall
automatically extend for an additional year on December 31, 2014 and each anniversary thereof
unless either party provides written notice, within ninety (90) days of the applicable anniversary
date, to the other party indicating such party’s desire to terminate the Employment.

3. Duties; Extent of Service.

(a) During the Employment, Employee shall serve as an employee of the Company with the title
and position of Executive Vice President & Chief Financial Officer. In this capacity, Employee
shall have all the authority and responsibility customarily associated with such position in a
company of the size and nature of the Company. Employee shall report directly to the Chief
Executive Officer of the Company or any successor in interest to the Company. Employee hereby
accepts such employment, agrees to serve the Company in the capacity indicated, and agrees to use
Employee’s best efforts in, and devote Employee’s full working time, attention, skill and energies
to, the advancement of the interests of the Company, CommScope Holding Company, Inc.
(“Parent”) and their direct and indirect subsidiaries and the performance of Employee’s
duties and responsibilities hereunder.

(b) The foregoing, however, shall not be construed as preventing employee from engaging in
religious, charitable or other community or non-profit activities that do not impair Employee’s
ability to fulfill Employee’s duties and responsibilities under this Agreement.

4. Compensation.

(a) During the Employment, the Company shall pay Employee a salary at the annual rate of
$465,000 per annum (the “Base Salary”). Such Base Salary may be increased at any time by
the Board of Directors of the Company (the “Board”). Such Base Salary shall be subject to
withholding under applicable law, shall be pro rated for partial years and shall be payable in
semi-monthly installments in accordance with the Company’s usual practice as in effect from time to
time.

(b) During the Employment, Employee shall be eligible to receive an annual bonus payment
pursuant to the CommScope Holding Company, Inc. Annual Incentive Plan (as such plan may be amended
and modified, the “AIP”). The Employee’s “Target Award” percentage shall be 85% of Base
Salary. Such “Target Award” percentage maybe increased at any time by the Board of Directors of
Parent or a committee thereof.

5. Benefits.

(a) During the Employment, Employee shall be entitled to participate in any and all vacation,
medical, pension, profit sharing, dental and life insurance plans and disability income plans,
retirement arrangements and other employment benefits of the Company, to the extent generally
available to the executive officers of the Company, as may be in effect from time to time in the
discretion of the Board. Such participation shall be subject to (i) the terms of the applicable
plan documents (including, as applicable, provisions granting discretion to the Board or any
administrative or other committee provided for therein or contemplated thereby) and (ii) generally
applicable policies of the Company, to the extent the terms of such participation are not covered
by the applicable plan documents, or if they are so covered, to the extent such policies are not
inconsistent therewith.

(b) The Company shall promptly reimburse Employee for all reasonable business expenses
incurred by Employee during the Employment, in accordance with the Company’s practices, as in
effect from time to time, subject to Section 17(d).

(c) Compliance with the provisions of this Section 5 shall in no way create or be deemed to
create any obligation, express or implied, on the part of the Company, Parent or any of their
direct and/or indirect subsidiaries with respect to the continuation of any particular benefit or
other plan or arrangement maintained by them or their subsidiaries as of or prior to the date
hereof or the creation and maintenance of any particular benefit or other plan or arrangement at
any time after the date hereof.

6. Termination and Termination Benefits. Notwithstanding the provisions of Section 2,
the Employment shall terminate under the circumstances set forth in this Section 6.

(a) Termination by the Company for Cause. The Employment may be terminated by the
Company for Cause (as defined below) without further liability on the part of the Company effective
immediately upon written notice to Employee. Only the following shall constitute “Cause”
for such termination:

(i) the commission of any act by Employee constituting financial dishonesty
against the Company or its subsidiaries (which act would be chargeable as a crime
under applicable law);

(ii) Employee’s engaging in any other act of dishonesty, fraud, intentional
misrepresentation, material misconduct, moral turpitude (not involving a traffic
offense), illegality or harassment which would, in the Company’s reasonable
judgment; (A) materially adversely affect the business or the reputation of the
Company or any of its subsidiaries with their respective current or prospective
customers, suppliers, lenders and/or other third parties with whom such entity does
or might do business, (B) expose the Company or any of its subsidiaries to material
damages, liabilities or penalties or (C) expose the Company or any of its
subsidiaries to criminal liabilities or penalties;

(iii) the willful and repeated failure by Employee to follow the lawful
directives of the Board of Directors of Parent;

(iv) any material violation of the Company’s written policies which would
customarily be punishable by termination of employment (as determined by the Board
of Directors of Parent in good faith), or willful and deliberate non-performance of
duty by Employee in connection with the business affairs of the Company or its
subsidiaries; or

(v) Employee’s material breach of this Agreement.

Notwithstanding the foregoing, there shall be no termination for Cause pursuant to Sections
6(a)(ii), (iii), (iv) or (v) without Employee first being given, not less ten (10) days written
notice by the Board of Directors of Parent, a reasonable opportunity to be heard before the Board
of Directors of Parent and a reasonable opportunity to cure the actions or omissions giving rise to
“Cause” (to the extent such cure is reasonably possible) within a reasonable time period.

(b) Termination by the Company Without Cause. The Employment may be terminated without
Cause by a vote of the Board of Directors of Parent and upon written notice to Employee. It is
expressly agreed and understood that if this Agreement is terminated by the Company without Cause
as provided in this Section 6(b), it shall not impair or otherwise affect Employee’s Continuing
Obligations (as defined below). Termination of employment upon expiration of the Term following a
decision by the Company not to extend the Term of employment pursuant to the second sentence of
Section 2 shall constitute a termination by Company without Cause.

(c) Termination by Employee for Good Reason. The Employment may be terminated by
Employee for Good Reason (as defined below), provided that (i) Employee first delivers to the
Company a written notice of such intended termination setting forth with specificity the occurrence
deemed to give rise to a right to terminate for Good Reason, and there shall have passed a
reasonable time (not less than 30 days) within which the Company may take action to correct,
rescind or otherwise substantially reverse the occurrence supporting termination for Good Reason as
identified by Employee and (ii) the event constituting “Good Reason” shall have occurred within the
sixty (60) day period immediately preceding the delivery of the notice referred to in clause (i) of
this Section 6(c). Only the following shall constitute “Good Reason”:

(i) any reduction in the Base Salary or in the “Target Award”;

(ii) without Employee’s express written consent, the failure to continue the
Employee as the Executive Vice President & Chief Financial Officer of the Company
and any successor in interest to the Company;

(iii) any material diminution in Employee’s duties or the assignment to
Employee of duties that are materially inconsistent with Employee’s then current
duties or title;

(iv) any other material breach by the Company of any of the provisions
described in this Agreement (including the failure to pay any amounts pursuant to
Section 4 above when due, but excluding reasonable delays in the payment of such
amounts due to unforeseen circumstances); and

(v) the relocation of Employee, without Employee’s prior written consent, to a
location 25 miles or more from Employee’s current principal place of employment.

(d) Termination by Employee other than for Good Reason. Employee’s employment under
this Agreement may be terminated by Employee other than for Good Reason by written notice to the
Board at least thirty (30) days prior to such termination. Termination of employment upon
expiration of the Term following a decision by Employee not to extend the Term of employment
pursuant to the second sentence of Section 2 shall constitute a termination by Employee other than
for Good Reason.

(e) Certain Termination Benefits. Unless otherwise specifically provided in this
Agreement or otherwise required by law, all compensation and benefits payable to Employee under
this Agreement shall terminate on the date of termination of the Employment. Notwithstanding the
foregoing, in the event of a termination of the Employment for any reason and subject to Section 17
below, the Company shall pay to Employee a lump sum in cash equal to the sum of (A) his Base Salary
through the date of termination to the extent not theretofore paid, (B) any annual bonus earned but
unpaid as of the date of termination for any previously completed fiscal year (and any such bonus
shall be treated as earned to the extent the Target Award criteria are determined to have been
satisfied for such year, without regard to whether such determination has been completed  by the
date of termination or whether Employee is employed on the normal payment date), (C) reimbursement
for any unreimbursed business expenses properly incurred by Employee in accordance with Company
policy prior to the date of termination, and (D) any accrued vacation pay to the extent not
theretofore paid (the sum of the amounts described in clauses (A) — (D) shall be hereinafter
referred to as the “Accrued Obligations”), payable on the 60th day following the
date of termination. In the event of a termination of the Employment without Cause pursuant to
Section 6(b) or in the event of a termination of the Employment with the Company for Good Reason
pursuant to Section 6(c), then, subject to Section 17, the Company shall provide to Employee the
following termination benefits (“Termination Benefits”) in addition to the Accrued
Obligations:

(i) except as otherwise provided in Section 19, an amount equal to two (2)
times the sum of (A) Employee’s Base Salary and (B) Employee’s Base Salary
multiplied by .85, payable in twenty-four (24) equal installments during a
twenty-four (24) month period following the date of termination (the
“Termination Benefits Period”) (such payment shall be subject to withholding
under applicable law and shall be made in accordance with the Company’s usual
payroll practice as in effect from time to time);

(ii) payment of any pro-rated bonus under the AIP with respect to the fiscal
year in which such termination occurs (payment shall be subject to withholding under
applicable law, shall be made at the time when the Company pays bonuses to its other
executive officers with respect to the applicable fiscal year, and shall be based on
actual performance for the applicable fiscal year) (the “Current Year Prorata
Bonus”); and

(iii) during the Termination Benefits Period, in periodic installments, in
accordance with the Company’s usual payroll practice as in effect from time to time,
a cash payment equal to the cost the Company would have incurred had Employee
continued group medical, dental, vision and/or prescription drug benefit coverage
for himself and his eligible dependents under the group health plan(s) sponsored by
Company covering Employee and his eligible dependents at the time of Employee’s
termination of employment (the “Health Coverage”) for the Termination
Benefits Period; provided, however, that (A) the cost of such Health Coverage shall
be determined at the same level of benefits as is generally available to similarly
situated employees and is subject to any modifications made to the same coverage
provided to similarly situated employees, including but not limited to termination
of the group health plans sponsored by Company; (B) the Company shall pay the excess
of the COBRA cost of such coverage over the amount that Employee would have had to
pay for such coverage if he had remained employed during the Termination Benefits
Period and paid the active employee rate for such coverage (the “COBRA
Cost”); (C) the time during which Employee receives the payments pursuant to
this Section 6(e)(iii) shall run concurrently with any period for which Employee is
eligible to elect health coverage under COBRA; and (D) such payment shall not limit
any rights Employee or his dependents may then have to receive retiree medical or
life insurance benefits then offered by the Company to the extent that Employee is
entitled to such benefits under the terms and conditions of the applicable plans or
policies.

(iv) if, at the end of the Termination Benefits Period, Employee is not
employed by another employer (including self-employment), Employee will receive an
amount equal to one-twelfth (1/12) of the sum of (A) Employee’s Base Salary and
(B) Employee’s Base Salary multiplied by .85 (such payment, subject to withholding
under applicable law, to be made on a monthly basis in accordance with the Company’s
usual payroll practice as in effect from time to time); provided however, that such
payments will immediately cease upon the earlier of (x) Employee’s employment
(including self-employment) by a subsequent employer and (y) six (6) calendar months
following the end of the Termination Benefits Period.  In addition, the benefits
described in Section 6(e)(iii) shall be continued until the earlier of (x) six (6)
months after the end of the Termination Benefits Period or (y) such time that
Employee obtains any of the coverages or benefits described in Section 6(e)(iii)
pursuant to a subsequent employer’s benefit plans.

The Termination Benefits set forth in (i) through (iv) above shall continue so long as Employee is
in compliance with Employee’s Continuing Obligations under this Agreement. The Company’s liability
for Termination Benefits set forth in (i) through (iv) above shall be reduced by the amount of any
severance, if any, actually paid to Employee pursuant to any severance pay plan of the Company.
Notwithstanding the foregoing, nothing in this Section 6(e) shall be construed to affect Employee’s
right to receive COBRA continuation entirely at Employee’s own cost to the extent that Employee may
continue to be entitled to COBRA continuation after Employee’s right to receive payments under
Section 6(e)(iii) ceases.

The Company and Employee agree that the Termination Benefits paid by the Company to Employee under
this Section 6(e) shall be in full satisfaction, compromise and release of any claims arising out
of any termination of Employee’s employment without Cause pursuant to Section 6(b), or a
termination of Employee’s employment with the Company for Good Reason pursuant to Section 6(c).
 The payment of the Termination Benefits shall be contingent upon Employee’s timely delivery as
provided below of a general release of any and all claims (other than those arising or otherwise
provided for under this Agreement) in a customary form reasonably satisfactory to the Company (and
without any additional obligations upon Employee beyond those provided for in, or otherwise
inconsistent with, this Agreement (a “Conforming Release”)), it being understood that no
Termination Benefits shall be provided unless and until Employee executes and delivers a Conforming
Release, except that (i) the Conforming Release shall not require a waiver of any of the Accrued
Obligations and (ii) Employee’s obligation to deliver such Conforming Release shall be contingent
upon the Company’s delivery of a Conforming Release to the Employee not later than ten (10) days
following the date of termination of Employment.   Provided such a Conforming Release has been
timely delivered to Employee, it must be executed, and all revocation periods must have expired,
within sixty (60) days after the date of termination of Employment, failing which such payment or
benefit shall be forfeited.  The Company may elect to commence payment of Termination Benefits at
any time during such sixty (60)-day period; provided, however, that if such sixty (60)-day period
begins in one taxable year and ends in the following taxable year, then the Company shall commence
payment of Termination Benefits in the second taxable year.  If such payment or benefit is exempt
from Section 409A of the Code, the Company may elect to make or commence payment of Termination
Benefits at any time during such sixty (60)-day period.

(f) Disability. If Employee shall be disabled so as to be unable to perform the
essential functions of Employee’s then existing position or positions under this Agreement with or
without reasonable accommodation (“Disability”), the Board may remove Employee from any
responsibilities and/or reassign Employee to another position with the Company for a period of six
(6) months or during the period of such Disability. Such removal and/or reassignment shall not give
Employee a right to terminate his employment for Good Reason. Notwithstanding any determination of
Employee’s Disability, Employee shall continue to receive Employee’s full Base Salary (less any
disability pay or sick pay benefits to which Employee may be entitled under the Company’s policies)
and benefits under Section 4 of this Agreement (except to the extent that Employee may be
ineligible for one or more such benefits under applicable plan terms) for any period of up to six
(6) months prior to his termination of employment. Employee’s employment may be terminated by the
Company at any time after six (6) months of Disability. In the event of such termination and
subject to Section 17, the Company shall have no further obligations except to pay the Accrued
Obligations and benefits as contemplated by this Section 6(f) through the date of such termination.
If any question shall arise as to whether during any period Employee is disabled so as to be unable
to perform the essential functions of Employee’s then existing position or positions with or
without reasonable accommodation, Employee may, and at the request of the Company shall, submit to
the Company a certification in reasonable detail by a physician selected by the Company to whom
Employee or Employee’s guardian has no reasonable objection as to whether Employee is so disabled
or how long such disability is expected to continue, and such certification shall for the purposes
of this Agreement be conclusive of the issue. Employee shall cooperate with any reasonable request
of the physician in connection with such certification. If such question shall arise and Employee
shall fail to submit such certification, the Company’s determination of such issue shall be binding
on Employee. Nothing in this Section 6(f) shall be construed to waive Employee’s rights, if any,
under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29
U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq.

(g) Death. Employee’s employment and all obligations of the Company and Employee
hereunder shall terminate in the event of the death of Employee, other than payment of the Current
Year Prorata Bonus (which shall be paid at the time when the Company pays bonuses to its other
executive officers with respect to the applicable fiscal year) and any Accrued Obligations.

(h) Continuing Obligations. Notwithstanding termination of this Agreement as provided
in this Section 6 or any other termination of Employee’s employment with the Company, Employee’s
obligations under Sections 7 and 8 hereof (other than as a result of termination pursuant to
Section 6(g)) and the Company’s obligations under Section 12 and Section 18 hereof (other than as a
result of termination pursuant to Section 6(a) or 6(d)) (the “Continuing Obligations”)
shall survive any termination of Employee’s employment with the Company at any time and for any
reason.

7. Non-Competition and Non-Solicitation. In consideration of Employee’s employment
hereunder and the additional benefits derived by Employee as a result of this Agreement, Employee
agrees to the following:

(a) Employee hereby agrees that during the period commencing on the date hereof and ending on
the date that is the later of (i) the second (2nd) anniversary of the date of the
termination of Employee’s employment with the Company for any reason regardless of the
circumstances thereof and (ii) in the case of a termination by the Company without Cause or a
resignation by Employee for Good Reason, if Employee receives benefits subsequent to the date
twenty four (24) month after the termination of employment pursuant to Section 6(e)(iv), the last
day that Employee receives benefits pursuant to such Section 6(e)(iv) (the “Noncompetition
Period”), Employee will not, without the express written consent of the Company, directly or
indirectly, anywhere in the United States or in any foreign country in which the Company has
conducted business, is conducting business or is presently contemplating conducting business,
engage in any activity which is, or participate or invest in, or provide or facilitate the
provision of financing to, or assist (whether as owner, part-owner, shareholder, member, partner,
director, officer, trustee, executive, agent or consultant, or in any other capacity), any
business, organization or Person other than the Company (or any subsidiary or affiliate of the
Company), including any such business, organization or Person involving, or which is, a family
member of Employee, whose business, activities, products or services are competitive with any of
the business, activities, products or services conducted or offered or proposed to be conducted or
offered by the Company or its subsidiaries during any period in which Employee is employed by the
Company or any of its subsidiaries. Without implied limitation, the foregoing covenant shall be
deemed to prohibit (other than through a general solicitation not targeted at the Company or its
subsidiaries) (a) hiring or engaging or attempting to hire or engage for or on behalf of Employee
or any such competitor any employee of the Company, Parent or any of their direct and/or indirect
subsidiaries, or any former employee of the Company, Parent or any of their direct and/or indirect
subsidiaries who was employed during the six (6) month period immediately preceding the date of
such attempt to hire or engage, (b) encouraging for or on behalf of Employee or any such competitor
any such employee to terminate his or her relationship or employment with the Company, Parent or
any of their direct and/or indirect subsidiaries, or (c) recruiting, soliciting or diverting for or
on behalf of Employee or any such competitor any customer of the Company, Parent or any of their
direct and/or indirect subsidiaries, or any former customer of the Company, Parent or any of their
direct and/or indirect subsidiaries who was a customer during the six (6) month period immediately
preceding the date of such recruitment, solicitation or diversion for the purpose of providing any
business, activities, products or services the same as or substantially similar to the business,
activities, products or services provided or offered by the Company.

Notwithstanding anything herein to the contrary, Employee may make passive investments in any
enterprise the shares of which are publicly traded if such investment constitutes less than five
percent (5%) of the equity of such enterprise.

Employee agrees that if a court of competent jurisdiction determines that any restriction, or
portion thereof, set forth in this Section 7 is overly restrictive and unenforceable, the court may
reduce or modify such restrictions to those which it deems reasonable and enforceable under the
circumstances, and as so reduced or modified, the parties hereto agree that the restrictions of
this Section 7 shall remain in full force and effect. Employee further agrees that if a court of
competent jurisdiction determines that any provision of this Section 7 is unenforceable, the
remaining provisions of this Section 7 and the remainder of this Agreement shall not be affected
thereby, and shall remain in full force and effect.

Employee acknowledges that the restrictions contained in this paragraph in view of the nature
of the Company’s business, are reasonable and necessary to protect the Company’s legitimate
business interests and that any violation of this paragraph would result in irreparable injury to
the Company, and that monetary damages may not be sufficient to compensate the Company for any
economic loss which may be incurred by reason of breach of the foregoing restrictive covenants. In
the event of a breach or a threatened breach by Employee of any provision in this paragraph, the
Company shall be entitled to a temporary restraining order and injunctive relief restraining
Employee from the commission of any breach, and to recover the Company’s attorneys’ fees, costs and
expenses related to the breach or threatened breach. Nothing contained in this paragraph shall be
construed as prohibiting the Company from pursuing any other remedies available to it for any
breach or threatened breach, including, without limitation, the recovery of money damages,
attorneys’ fees and costs. The restrictions in this paragraph shall each be construed as
independent of any other provisions in this Agreement, and the existence of any claim or cause of
action by Employee against the Company, whether predicated on this Agreement or otherwise, shall
not constitute a defense to the enforcement of this Agreement.

If Employee violates any of the restrictions contained in this Section, the restrictive period
will be suspended and will not run in favor of Employee from the time of the commencement of any
violation until the time when Employee cures the violation to the Company’s reasonable
satisfaction.

(b) During and after Employee’s employment, Employee shall cooperate fully with the Company in
the defense or prosecution of any claims or actions now in existence or which may be brought in the
future against or on behalf of the Company that relate to events or occurrences that transpired
while Employee was employed by the Company. Employee’s full cooperation in connection with such
claims or actions shall include, but not be limited to, being available to meet with counsel to
prepare for discovery or trial and to act as a witness on behalf of the Company at mutually
convenient times. During and after the Employment, Employee also shall cooperate fully with the
Company in connection with any investigation or review of any federal, state or local regulatory
authority as any such investigation or review relates to events or occurrences that transpired
while Employee was employed by the Company. Subject to Section 17(d), the Company shall reimburse
Employee for any reasonable fees and reasonable out-of-pocket expenses incurred in connection with
Employee’s performance of obligations pursuant to this Section 7(b) and such cooperation shall be
at reasonable times and upon reasonable advance notice.

(c) Employee agrees, while he is employed by the Company, to offer or otherwise make known or
available to it, as directed by the Board of the Company and without additional compensation or
consideration, any business prospects, contracts or other business opportunities that Employee may
discover, find, develop or otherwise have available to Employee in the Company’s general industry
and further agrees that any such prospects, contacts or other business opportunities shall be the
property of the Company.

8. Employee Agreement Regarding Non-Disclosure and Development. Employee represents,
warrants and covenants that all patents, patent applications, rights to inventions, copyright
registrations and other license, trademark and trade name rights heretofore owned by Employee and
relating to the business of the Company, Parent or any of their direct and/or indirect subsidiaries
have been or will be duly transferred to the Company on or prior to the date of termination of
employment with the Company. Employee agrees and understands that in Employee’s position with the
Company, Parent or any of their direct and/or indirect subsidiaries and performance of his or her
responsibilities, duties and services for the Company, Parent or any of their direct and/or
indirect subsidiaries, as the case may be, Employee has been exposed to non-public information
relating to the confidential affairs of the Company, Parent or any of their direct and/or indirect
subsidiaries, including but not limited to technical information, intellectual property, business
and marketing plans, strategies, customer information, other information concerning the products,
promotions, development, financing, expansion plans, business policies and practices of the
Company, Parent or any of their direct and/or indirect subsidiaries, and other forms of
confidential information, trade secrets and/or confidential information in the nature of trade
secrets of the Company, Parent or any of their direct and/or indirect subsidiaries
(“Confidential Information”). The provisions of this confidentiality covenant shall not
apply to confidential information which is (i) generally known to the industry or to the public
other than as a result of Employee’s breach of this covenant or any breach of other confidentiality
obligations by third Persons, (ii) made legally available to Employee by a third Party without
breach of any confidentiality obligation, or (iii) required by law to be disclosed, provided that
Employee shall give prompt notice to the Company of any such requirement, shall disclose no more
information than is required, and shall cooperate with attempts by the Company to obtain a
protective order or similar treatment. Employee acknowledges and agrees that at any time
hereafter Employee will not disclose Confidential Information, either directly or indirectly, to
any Person other than the Company, Parent or any of their direct and/or indirect subsidiaries (or
their professional advisors who are bound by confidentiality obligations) without the prior written
consent of the Company or Parent, as appropriate, except for such disclosure that Employee in good
faith believes to be necessary or desirable for the performance of his duties hereunder during the
Term. This confidentiality covenant has no temporal, geographical or territorial restriction.
Except as otherwise expressly agreed to by the Company, Parent or any of their direct and/or
indirect subsidiaries, as appropriate, on or promptly following the date of termination of
Employee’s employment with the Company, Employee will supply to the Company, Parent or any of their
direct and/or indirect subsidiaries, as appropriate, all property, keys, mobile phones, computer
equipment, software data files, notes, memoranda, writings, lists, files, reports, customer lists,
correspondence, tapes, disks, cards, surveys, maps, logs, machines, technical data or any other
tangible product or document (and any copies, in whatever medium, thereof) which has been produced
by, received by or otherwise submitted to Employee during his or her employment with the Company.
Any such data or property (including copies thereof) stored on computer, software data files or
other equipment belonging to Employee (or to which Employee otherwise has lawful access after the
date hereof) shall be deleted by Employee immediately following the termination of Employee’s
employment with the Company.

9. Parties in Interest; Certain Remedies. It is specifically understood and agreed
that this Agreement is intended to confer a benefit, directly or indirectly, on the Company, Parent
and any of their direct and/or indirect subsidiaries, and that any breach of the provisions of
Sections 7 and 8 of this Agreement by Employee will result in irreparable injury to the Company,
Parent and their direct and/or indirect subsidiaries, that the remedy at law alone will be an
inadequate remedy for such breach and that, in addition to any other remedy it may have, the
Company, Parent and any of their direct and/or indirect subsidiaries shall be entitled to enforce
the specific performance of Sections 7 and 8 of this Agreement by Employee through both temporary
and permanent injunctive relief without the necessity of posting a bond or proving actual damages,
but without limitation of their right to damages and any and all other remedies available to them,
it being understood that injunctive relief is in addition to, and not in lieu of, such other
remedies.

10. Dispute Resolution.

(a) All disputes, claims, or controversies arising out of or relating to this Agreement or any
other agreement executed and delivered pursuant to this Agreement or the negotiation, validity or
performance hereof and thereof or the transactions contemplated hereby and thereby, or the rights
and obligations of the parties hereunder or thereunder, that are not resolved by mutual agreement
shall be resolved solely and exclusively by binding arbitration to be conducted before Judicial
Arbitration and Mediation Services, Inc. (“JAMS”). The arbitration shall be held in New
York, New York before a single arbitrator and shall be conducted in accordance with the rules and
regulations promulgated by JAMS unless specifically modified herein.

(b) The parties covenant and agree that the arbitration shall commence within one hundred
eighty (180) days of the date on which a written demand for arbitration is filed by any party
hereto. In connection with the arbitration proceeding, the arbitrator shall have the power to order
the production of documents by each party and any third-party witnesses. In addition, each party
may take up to three depositions as of right, and the arbitrator may in his or her discretion allow
additional depositions upon good cause shown by the moving party. However, the arbitrator shall not
have the power to order the answering of interrogatories or the response to requests for admission.
In connection with any arbitration, each party shall provide to the other, no later than seven (7)
business days before the date of the arbitration, the identity of all persons that may testify at
the arbitration and a copy of all documents that may be introduced at the arbitration or considered
or used by a party’s witness or expert. The arbitrator’s decision and award shall be made and
delivered within six (6) months of the selection of the arbitrator. The arbitrator’s decision shall
set forth a reasoned basis for any award of damages or finding of liability. The arbitrator shall
not have power to award damages in excess of actual compensatory damages and shall not multiply
actual damages or award punitive damages or any other damages that are specifically excluded under
this Agreement, and each party hereby irrevocably waives any claim to such damages.

(c) The parties covenant and agree that they will participate in the arbitration in good faith
and that they will, except as provided below, (i) bear their own attorneys’ fees, costs and
expenses in connection with the arbitration, and (ii) share equally in the fees and expenses
charged by JAMS. The arbitrator may in his or her discretion assess costs and expenses (including
the reasonable legal fees and expenses of the prevailing party) against any party to a proceeding.
Any party unsuccessfully refusing to comply with an order of the arbitrators shall be liable for
costs and expenses, including attorneys’ fees, incurred by the other party in enforcing the award.
This Section 10(c) applies equally to requests for temporary, preliminary or permanent injunctive
relief, except that in the case of temporary or preliminary injunctive relief any party may proceed
in court without prior arbitration for the purpose of avoiding immediate and irreparable harm or to
enforce the provisions of Section 9.

(d) Each of the parties hereto irrevocably and unconditionally consents to the exclusive
jurisdiction of JAMS to resolve all disputes, claims or controversies arising out of or relating to
this Agreement or any other agreement executed and delivered pursuant to this Agreement or the
negotiation, validity or performance hereof and thereof, or the transactions contemplated hereby
and thereby, or the rights and obligations of the parties hereunder or thereunder, and further
consents to the sole and exclusive jurisdiction of the courts of the State of New York for the
purposes of enforcing the arbitration provisions of this Section 10. Each party further irrevocably
waives any objection to proceeding before JAMS based upon lack of personal jurisdiction or to the
laying of venue and further irrevocably and unconditionally waives and agrees not to make a claim
in any court that arbitration before JAMS has been brought in an inconvenient forum. Each of the
parties hereto hereby consents to service of process by registered mail at the address to which
notices are to be given. Each of the parties hereto agrees that its or his submission to
jurisdiction and its or his consent to service of process by mail is made for the express benefit
of the other parties hereto.

11. Notices. All notices, requests, demands and other communications hereunder shall
be in writing and shall be deemed to have been duly given if delivered personally or mailed by
certified or registered mail (return receipt requested) as follows:

To the Company:

CommScope, Inc.

1100 CommScope Place, SE

Hickory, NC 28602

Attention: General Counsel

To Employee:

Mark A. Olson

121 42nd Avenue Ct NW

Hickory, NC 28601

or to such other address of which any party may notify the other parties as provided above. Notices
shall be effective as of the date of such delivery or mailing.

12. Indemnification. Without limiting Employee’s rights to indemnification in any
other agreement to which he is a party or a third party beneficiary, Employee shall be entitled to
indemnification from the Company and Parent in connection with his service as an officer and a
director of the Parent, the Company and any of its direct and indirect subsidiaries to the extent
set forth in the Certificate of Incorporation, as amended, and By-laws, as amended, of the Company
and the Parent.

13. Scope of Agreement. The parties acknowledge that the time, scope, geographic area
and other provisions of Section 7 and Section 8 have been specifically negotiated by sophisticated
parties and agree that all such provisions are reasonable under the circumstances of the
transactions contemplated hereby, and are given as an integral and essential part of the
transactions contemplated hereby. Employee has independently consulted with counsel and has been
advised in all respects concerning the reasonableness and propriety of the covenants contained
herein, with specific regard to the business to be conducted by Company, Parent or any of their
direct and/or indirect subsidiaries, and represents that the Agreement is intended to be, and shall
be, fully enforceable and effective in accordance with its terms.

14. Severability. In the event that any covenant contained in this Agreement shall be
determined by any court of competent jurisdiction to be unenforceable by reason of its extending
for too great a period of time or over too great a geographical area or by reason of its being too
extensive in any other respect, it shall be interpreted to extend only over the maximum period of
time for which it may be enforceable and/or over the maximum geographical area as to which it may
be enforceable and/or to the maximum extent in all other respects as to which it may be
enforceable, all as determined by such court in such action. The existence of any claim or cause of
action which Employee may have against the Company, Parent or any of their direct and/or indirect
subsidiaries shall not constitute a defense or bar to the enforcement of any of the provisions of
this Agreement.

15. Counterparts Facsimile Signatures. This Agreement may be executed in one or more
counterparts, all of which taken together shall constitute one and the same Agreement. Each party
may rely upon the execution of this Agreement by the other party via the facsimile signature as if
such facsimile signature were an original signature.

16. Miscellaneous. This Agreement shall be governed by and construed under the laws of
the State of North Carolina, without consideration of its choice of law provisions, and shall not
be amended, modified or discharged in whole or in part except by an agreement in writing signed by
both of the parties hereto. The failure of either of the parties to require the performance of a
term or obligation or to exercise any right under this Agreement or the waiver of any breach
hereunder shall not prevent subsequent enforcement of such term or obligation or exercise of such
right or the enforcement at any time of any other right hereunder or be deemed a waiver of any
subsequent breach of the provision so breached, or of any other breach hereunder. This Agreement
shall inure to the benefit of and be binding upon and assignable to, successors of the Company by
way of merger, consolidation or sale and may not be assigned by Employee. This Agreement supersedes
and terminates all prior understandings and agreements between the parties (or their predecessors)
relating to the subject matter hereof; provided, however, this agreement shall not alter or limit
the obligations of Employee pursuant to any other confidentiality, noncompetition, nonsolicitation
or similar agreement applicable to Employee. For the avoidance of doubt, the Severance Agreement is
hereby terminated without any liability to any party thereto. For purposes of this Agreement, the
term “subsidiary” means any corporation more than 50 percent of whose outstanding voting
securities, or any partnership, joint venture or other entity more than 50 percent of whose total
equity interest, is directly or indirectly owned by such Person; and an “affiliate” of a Person
shall mean, with respect to a Person, any Person which directly or indirectly controls, is
controlled by, or is under common control with such Person. The Company and Employee hereby
acknowledge and agree that the changes to the terms and conditions of Employee’s employment
pursuant to this Agreement shall not constitute “Good Reason,” as such term is defined in Section
6(c) herein or in the Severance Agreement.

17. Internal Revenue Code Section 409A.

(a) It is the intent of the parties that this Agreement shall be interpreted and administered
in a manner so that any amount or benefit payable hereunder shall be paid or provided in a manner
that is either exempt from or compliant with the requirements Section 409A of the Internal Revenue
Code of 1986, as amended (the “Code”), and applicable Internal Revenue Service guidance and
Treasury Regulations issued thereunder (and any applicable transition relief under Section 409A of
the Code). Neither the Company nor its directors, officers, employees or advisers shall be held
liable for any taxes, interest, penalties or other monetary amounts owed by Employee as a result of
the application of Section 409A of the Code.

(b) Notwithstanding anything in this Agreement to the contrary, to the extent that the
severance payments under Section 6(e)(i), (ii) and (iii), and any other amount or benefit that
would constitute non-exempt “deferred compensation” for purposes of Section 409A of the Code would
otherwise be payable or distributable hereunder, or a different form of payment of such non-exempt
deferred compensation would be effected, by reason of a Change in Control or Employee’s termination
of employment, such non-exempt deferred compensation will not be payable or distributable to
Employee, and/or such different form of payment will not be effected, by reason of such
circumstances unless the circumstances giving rise to such Change in Control or termination of
employment, as the case may be, meet any description or definition of “change in the ownership or
effective control of a corporation, or a change in the ownership of a substantial portion of the
assets of a corporation” or “separation from service,” as the case may be, in Section 409A of the
Code and applicable regulations (without giving effect to any elective provisions that may be
available under such definition). This provision does not prohibit the vesting of any amount of
non-exempt deferred compensation upon a Change in Control or termination of Employee’s employment,
however defined. If this provision prevents the payment or distribution of any non-exempt deferred
compensation, such payment or distribution shall be made on the date, if any, on which an event
occurs that constitutes a Section 409A-compliant “change in control event” or “separation from
service,” as the case may be. If this provision prevents the application of a different form of
payment of any amount or benefit, such payment shall be made in the same form as would have applied
absent such designated event or circumstance.

(c) Each payment of Termination Benefits under Section 6(e) of this Agreement shall be
considered a separate payment, as described in Treas. Reg. Section 1.409A-2(b)(2), for purposes of
Section 409A of the Code.

(d) If Employee is entitled to be paid or reimbursed for any taxable expenses under this
Agreement, and such payments or reimbursements are includible in Employee’s federal gross taxable
income, the amount of such expenses reimbursable in any one calendar year shall not affect the
amount reimbursable in any other calendar year, and the reimbursement of an eligible expense must
be made no later than December 31 of the year after the year in which the expense was incurred. No
right of Employee to reimbursement of expenses under this Agreement shall be subject to liquidation
or exchange for another benefit. Employee’s rights to payment or reimbursement of expenses
pursuant to Section 5(b) of this Agreement shall expire at the end of two (2) years after the date
of termination of this Agreement.

(e) Notwithstanding anything in this Agreement to the contrary, if any amount or benefit that
would constitute non-exempt “deferred compensation” for purposes of Section 409A of the Code would
otherwise be payable or distributable under this Agreement by reason of Employee’s separation from
service during a period in which he is a Specified Employee (as defined herein), then, subject to
any permissible acceleration of payment by the Company under Treas. Reg. Section 1.409A-3(j)(4)(ii)
(domestic relations order), (j)(4)(iii) (conflicts of interest), or (j)(4)(vi) (payment of
employment taxes): (i) the amount of such non-exempt deferred compensation that would otherwise be
payable during the six-month period immediately following Employee’s separation from service will
be accumulated through and paid or provided on the first day of the seventh month following
Employee’s separation from service (or, if Employee dies during such period, within 30 days after
his death) (in either case, the “Required Delay Period”); and (ii) the normal payment or
distribution schedule for any remaining payments or distributions will resume at the end of the
Required Delay Period. For purposes of this Agreement, the term “Specified Employee” has
the meaning given such term in Code Section 409A and the final regulations thereunder.

18. Internal Revenue Code Section 280G Gross-Up.

(a)  In the event that it shall be determined that any payment (other than the payment
provided for in this Section 18) or distribution of any type to or for the benefit of Employee, by
the Parent, any affiliate of the Parent, any “Person” (within the meaning of Sections 13(d) and
14(d) of the Securities Exchange Act of 1934, as amended, a “Person”) who acquires
ownership or effective control of the Parent or ownership of a substantial portion of the Parent’s
assets (within the meaning of Section 280G of the Code, and the regulations thereunder) or any
affiliate of such Person, whether paid or payable or distributed or distributable pursuant to the
terms of this Agreement or otherwise (the “Total Payments”), is or will be subject to the
excise tax imposed by Section 4999 of the Code or any interest or penalties with respect to such
excise tax (such excise tax, together with any such interest and penalties, are collectively
referred to as the “Excise Tax”), then Employee shall be entitled to receive an additional
payment (a “Gross-Up Payment”) in an amount such that after payment by Employee of all
taxes (including any interest or penalties imposed with respect to such taxes), including any
income tax, employment tax or Excise Tax, imposed upon the Gross-Up Payment, Employee retains an
amount of the Gross-Up Payment equal to the Excise Tax imposed upon the Total Payments.

 

(b)  All mathematical determinations, and all determinations as to whether any of the Total
Payments are “parachute payments” (within the meaning of Section 280G of the Code), that are
required to be made under this Section 18, including determinations as to whether a Gross-Up
Payment is required, the amount of such Gross-Up Payment and amounts relevant to the last sentence
of this Section 18(b), shall be made by an independent accounting firm selected by Employee from
among the six (6) largest accounting firms in the United States (the “Accounting Firm”),
which shall provide its determination (the “Determination”), together with detailed
supporting calculations regarding the amount of any Gross-Up Payment and any other relevant matter,
both to the Company and Employee by no later than ten (10) days following the date of termination,
if applicable, or such earlier time as is requested by the Company or Employee (if Employee
reasonably believes that any of the Total Payments may be subject to the Excise Tax).  If the
Accounting Firm determines that no Excise Tax is payable by Employee, it shall furnish Employee and
the Company with an opinion reasonably acceptable to Employee and the Company that no Excise Tax is
payable (including the reasons therefor) and that Employee has substantial authority not to report
any Excise Tax on his federal income tax return.  If a Gross-Up Payment is determined to be
payable, it shall be paid to Employee within twenty (20) days after the Determination (and all
accompanying calculations and other material supporting the Determination) is delivered to the
Company by the Accounting Firm.  Any determination by the Accounting Firm shall be binding upon the
Company and Employee, absent manifest error.  As a result of uncertainty in the application of
Section 4999 of the Code at the time of the initial determination by the Accounting Firm hereunder,
it is possible that Gross-Up Payments not made by the Company should have been made
(“Underpayment”), or that Gross-Up Payments will have been made by the Company which should
not have been made (“Overpayments”).  In either such event, the Accounting Firm shall
determine the amount of the Underpayment or Overpayment that has occurred.  In the case of an
Underpayment, the amount of such Underpayment (together with any interest and penalties payable by
Employee as a result of such Underpayment) shall be promptly paid by the Company to or for the
benefit of Employee.  In the case of an Overpayment, Employee shall, at the direction and expense
of the Company, take such steps as are reasonably necessary (including the filing of returns and
claims for refund), follow reasonable instructions from, and procedures established by, the
Company, and otherwise reasonably cooperate with the Company to correct such Overpayment, provided,
however, that (i) Employee shall not in any event be obligated to return to the Company an amount
greater than the net after-tax portion of the Overpayment that he has retained or has recovered as
a refund from the applicable taxing authorities and (ii) this provision shall be interpreted in a
manner consistent with the intent of Section 18(a), which is to make Employee whole, on an
after-tax basis, from the application of the Excise Tax, it being understood that the correction of
an Overpayment may result in Employee repaying to the Company an amount which is less than the
Overpayment. The fees and expenses of the Accounting Firm shall be paid by the Company.

 

(c)  Any Gross-Up Payment shall be paid no later than the last day of Employee’s taxable year
next following Employee’s taxable year in which the taxes imposed in respect of which the Gross-Up
Payment is being made are remitted to the applicable taxing authority.

19. Acceleration of Benefits in Connection with a Change of Control.

(a) If, during the Term, the Employee’s employment with the Company shall be terminated by the
Company without Cause or a resignation by Employee for Good Reason within twenty-four (24) months
following a Change in Control (as defined below), the compensation and benefits provided for in
Section 6(e)(i), subject to Section 17, shall be paid in a single lump sum cash payment within ten
(10) days after Employee’s date of termination (or earlier, if required by applicable law) in lieu
of the periodic payments contemplated by Section 6(e)(i).

(b) For purposes of this Agreement, “Change in Control” shall mean any of the following:

 

(i) an acquisition (other than directly from the Parent) of any securities issued by
Parent which generally entitle the holder thereof to vote for the election of directors of
Parent (“Voting Securities”) by any Person, immediately after which such Person has
Beneficial Ownership (as defined below) of more than thirty-three percent (33%) of (i) the
then-outstanding Shares (as defined below) or (ii) the combined voting power of the Parent’s
then-outstanding Voting Securities; provided, however, that in determining whether a Change
in Control has occurred pursuant to this paragraph (a), the acquisition of Shares or Voting
Securities in a Non-Control Acquisition (as hereinafter defined) shall not constitute a
Change in Control.  A “Non-Control Acquisition” shall mean an acquisition by (i) an
employee benefit plan (or a trust forming a part thereof) maintained by (A) the Parent or
(B) any corporation or other Person the majority of the voting power, voting equity
securities or equity interest of which is owned, directly or indirectly, by the Parent (for
purposes of this definition, a “Related Entity”), (ii) the Parent or any Related
Entity, or (iii) any Person in connection with a Non-Control Transaction (as hereinafter
defined);

 

(ii) the individuals who, as of the Effective Date, are members of the board of the
directors of the Parent (the “Incumbent Board”), cease for any reason to constitute
at least two-thirds of the members of the Board of Directors of the Parent or, following a
Post-Effective Date Merger (as hereinafter defined), the board of (i) the corporation
resulting from such Post-Effective Date Merger (the “Surviving Corporation”), if
fifty percent (50%) or more of the combined voting power of the then-outstanding voting
securities of the Surviving Corporation is not Beneficially Owned, directly or indirectly,
by another Person (a “Parent Corporation”) or (ii) if there is one or more than one
Parent Corporation, the ultimate Parent Corporation; provided, however, that, if the
election, or nomination for election by the Parent’s common shareholders, of any new
director was approved by a vote of at least two-thirds of the Incumbent Board, such new
director shall, for purposes of this Agreement, be considered a member of the Incumbent
Board; and provided, further, however, that no individual shall be considered a member of
the Incumbent Board if such individual initially assumed office as a result of an actual or
threatened solicitation of proxies or consents by or on behalf of a Person other than the
Board of Directors of the Parent (a “Proxy Contest”), including by reason of any
agreement intended to avoid or settle any Proxy Contest; or

 

(iii) the consummation of:

 

(1) a merger, consolidation or reorganization (x) with or into the Parent or (y) in
which securities of the Parent are issued (a “Post-Effective Date Merger”), unless
such Post-Effective Date Merger is a “Non-Control Transaction.” A “Non-Control
Transaction” shall mean a Post-Effective Date Merger in which:

 

(A) the shareholders of the Parent immediately before such Post-Effective Date
Merger own directly or indirectly immediately following such Post-Effective Date
Merger at least a majority of the combined voting power of the outstanding voting
securities of (1) the Surviving Corporation, if there is no Parent Corporation or
(2) if there is one or more than one Parent Corporation, the ultimate Parent
Corporation;

 

(B) the individuals who were members of the Incumbent Board immediately prior
to the execution of the agreement providing for such Post-Effective Date Merger
constitute at least a majority of the members of the board of directors of (1) the
Surviving Corporation, if there is no Parent Corporation, or (2) if there is one or
more than one Parent Corporation, the ultimate Parent Corporation; and

 

(C) no Person other than (1) Company or another corporation that is a party to
the agreement of Post-Effective Date Merger, (2) any Related Entity, or (3) any
employee benefit plan (or any trust forming a part thereof) that, immediately prior
to the Post-Effective Date Merger, was maintained by the Parent or any Related
Entity, or (4) any Person who, immediately prior to the Post-Effective Date Merger
had Beneficial Ownership of thirty-three percent (33%) or more of the then
outstanding Shares or Voting Securities, has Beneficial Ownership, directly or
indirectly, of thirty-three percent (33%) or more of the combined voting power of
the outstanding voting securities or common stock of (x) the Surviving Corporation,
if there is no Parent Corporation, or (y) if there is one or more than one Parent
Corporation, the ultimate Parent Corporation.

 

(2) a complete liquidation or dissolution of the Parent; or

 

(3) the sale or other disposition of all or substantially all of the assets of the
Parent and its subsidiaries taken as a whole to any Person (other than (x) a transfer to a
Related Entity or (y) the distribution to the Parent’s shareholders of the stock of a
Related Entity or any other assets).

 

Notwithstanding the foregoing, a Change in Control shall not be deemed to occur solely because any
Person (the “Subject Person”) acquired Beneficial Ownership of more than the permitted
amount of the then outstanding Shares or Voting Securities as a result of the acquisition of Shares
or Voting Securities by the Parent which, by reducing the number of Shares or Voting Securities
then outstanding, increases the proportional number of Shares Beneficially Owned by the Subject
Persons; provided that if a Change in Control would occur (but for the operation of this sentence)
as a result of the acquisition of Shares or Voting Securities by the Parent and, after such share
acquisition by the Parent, the Subject Person becomes the Beneficial Owner of any additional Shares
or Voting Securities and such Beneficial Ownership increases the percentage of the then outstanding
Shares or Voting Securities Beneficially Owned by the Subject Person, then a Change in Control
shall occur.

(c) For purposes of this Agreement, “Beneficially Owned,” “Beneficial
Ownership” and “Beneficially Owning” shall have the meanings applicable under Rule
13d-3 promulgated under the Securities Exchange Act of 1934, as amended.

(d) For purposes of this Agreement, “Shares” shall mean the common stock, par value
$0.01 per share, of the Parent and any other securities into which such shares are changed or for
which such shares are exchanged.

20. Non-exclusivity of Rights. Nothing in this Agreement shall prevent or limit
Employee’s continuing or future participation in any employee benefit plan, program, policy or
practice provided by the Company and for which Employee may qualify, except as specifically
provided herein. Amounts that are vested benefits or which Employee is otherwise entitled to
receive under any plan, policy, practice or program of the Company at or subsequent to the date of
termination of Employment shall be payable in accordance with such plan, policy, practice or
program except as explicitly modified by this Agreement. For the avoidance of doubt, no provision
of this Agreement is meant to modify or limit Employee’s right to receive his vested supplemental
executive retirement plan benefits, if any, and to exercise his vested options, if any, in
accordance with the terms of the applicable plan documents, related agreements and operative prior
elections.

21. Full Settlement; No Mitigation. The Company’s obligation to make the payments
provided for in this Agreement and otherwise to perform its obligations hereunder shall not be
affected by any set-off, counterclaim, recoupment, defense or other claim, right or action which
the Company may have against Employee or others. In no event shall Employee be obligated to seek
other employment or take any other action by way of mitigation of the amounts payable to Employee
under any of the provisions of this Agreement and, except as set forth in Section 6(e)(iv), such
amounts shall not be reduced whether or not Employee obtains other employment.

[Remainder of Page Intentionally Left Blank]

1

IN WITNESS WHEREOF, the parties have executed this Agreement under seal as of the date first
set forth above.

	 	 	 
	                                                     
	 	COMPANY

	                                                  
	 	

	                                                  
	 	COMMSCOPE, INC.

	                                                  
	 	

	                                                  
	 	By: /s/ Marvin S. Edwards, Jr.

	 	 	 

	                                                  
	 	Name: Marvin S. Edwards, Jr.

	                                                  
	 	Title: President and Chief Executive Officer

	                                                  
	 	

	                                                  
	 	

	                                                  
	 	

	                                                  
	 	EMPLOYEE:

	                                                  
	 	

	                                                  
	 	

	                                                  
	 	

	                                                  
	 	/s/ Mark A. Olson

	 	 	 

	                                                  
	 	Mark A. Olson

2blfs_ex1044.htm

Exhibit 10.44

 

MANUFACTURING SERVICES AGREEMENT

This Manufacturing Services Agreement (“Agreement”) is entered into and is effective as of the 22nd day of December, 2011 (the “Effective Date”), by and between BioLife Solutions, Inc, a Delaware corporation with offices at 3303 Monte Villa Parkway, Suite 310, Bothell, WA  98021 (“BioLife”), and Organ Recovery Systems, Inc., a Delaware corporation with offices at One Pierce Place, Suite 475W, Itasca, IL 60143 (“ORS”).

This Agreement is intended to establish the master terms under which BioLife will provide Services to manufacture the ORS “Products” (as defined below).

Therefore, ORS and BioLife agree as follows:

1.           Definitions

As used in this Agreement, the following capitalized terms shall have the meanings set forth below:

1.1           “Affiliate” means, with respect to a referenced party, another entity that controls, is controlled by, or is under common control with, such party for so long as such control exists.

1.2           “Batch” means the quantity of Product, in a specified number of units (e.g. liters and/or bags), of uniform character and quality, yielded from the same cycle of Manufacturing using a specific quantity of materials.

 

1.3           “Batch Record” means the document created by BioLife as and after each Batch is Manufactured. Each Batch Record shall reflect and incorporate the relevant aspects of the Master Batch Record, the applicable Certificate of Analysis, the Certificate of Compliance, and any Deviation Reports issued with respect to such Batch.

 

1.4.           “Business Day” means any days between and including Monday through Friday and does not include public holidays and weekends.

1.5           “Certificate of Analysis” means a certificate that accompanies each shipment of a Batch of Product by BioLife to ORS in which BioLife certifies that such Batch of Product meets Product Specifications.

 

1.6           “Certificate of Compliance” means a certificate attesting that a particular Batch of Product was Manufactured in accordance with the applicable Manufacturing Standards.

 

1.7            “Confidential Information” has the meaning stated in the Mutual Nondisclosure Agreement signed by BioLife and ORS dated as of September 8, 2011, which shall remain in full force and effect in accordance with its terms.

1.8           “FDA” means the United States Food and Drug Administration or any successor agency thereof, and any other authority or agency of any other country or territory outside the United States with regulatory oversight for the manufacturing, processing, use, marketing and/or sale of pharmaceutical products or medical devices.

1.9           “Good Manufacturing Practices”, “GMP”, “cGMP” and words to a similar effect mean the guidelines established by the FDA by which drugs or medical devices are manufactured, as in effect from time to time, and the related regulations and FDA guidance documents in effect from time to time, and equivalent regulation in such other territories as are mutually agreed by the parties from time to time in writing, provided that in the event of any conflict among the applicable laws of the United States and other countries or territories, current Good Manufacturing Practices as specified in the United States Code of Federal Regulations shall be applied unless another territory is specifically agreed to in writing.

1.10           “Intellectual Property” means inventions, discoveries, developments, methods, innovations, designs, modifications, specifications (including without limitation the Product Specifications), and improvements, whether or not patentable, patent rights, inventions, designs, and improvements; copyrights (including derivative works); trade secrets, ideas, process techniques, procedures, know-how and data (including all rights therein); and all intellectual property rights in any of the foregoing of any kind, whether or not protectable under patent, trademark, copyright or similar laws of any jurisdiction.

1.11           “Facilities” means BioLife’s facility located at 3301 Monte Villa Parkway, Bothell, Washington, and all other facilities used by BioLife in the Manufacturing of Products which are approved in advance in writing by ORS.

  

 

  

 

1.12           “Manufacture” or “Manufacturing” means all activities performed by BioLife relating to the ORS Products, including but not limited to the manufacturing procedures, or any part thereof, involved in compounding all ingredients for the Product,  raw material purchasing, testing and release, formulations, the manufacturing and filling of Product, quality control testing and quality assurance activities, release and stability testing, and the Packaging of Product for shipment to ORS, all in accordance with this Agreement.

1.13           “Manufacturing Standards” means Manufacturing in accordance with the Master Batch Record and cGMP (subject in each case to any Deviations that do not compromise the quality of the Product or adherence of the Product to regulatory requirements) to produce a Product that meets the Product Specifications.

 

1.14           “Master Batch Records” means the document approved in writing by both parties, and as may be amended from time to time in writing by the parties in accordance with this Agreement, specifying the complete set of formal instructions agreed upon by the parties for the Manufacturing of Products, including but not limited to material descriptions, formulae, Manufacturing processes and procedures, in process testing specifications, Product Specifications, analytic test specifications, and Packaging and shipping specifications, each for the applicable Products.

1.15           “Package” and “Packaging” means the act of inspecting, labeling, and packing the Product into the specified shipping containers in accordance with the Product Specifications.

 

1.16           “Products” means, with respect to each of the ORS products listed in Appendix A or later made subject to this Agreement by an amendment signed by BioLife and ORS, the finished products in final size, presentation and packaging in compliance with the terms of this Agreement and all applicable laws, rules and regulations.

1.17           “Product Specifications” means the written specifications and quality standards, including standards for all ingredients and raw materials to be used in Products, tests, analytical procedures and acceptance criteria, and packaging, labeling and shipping components used in Manufacturing of Product, that are established to confirm the characteristics and quality of Products as agreed upon initially in writing by the parties, and as subsequently set forth in or referenced in the mutually agreed upon Master Batch Record, as amended from time to time by written agreement of the Parties in accordance with the procedures set forth in this Agreement.

 

1.18           “Project” refers to the contractual, financial and project protocol details of the Services, including without limitation, the Product Specifications and the Master Batch Records, each subject to the terms and conditions as agreed in writing between BioLife and ORS for each job to be performed at BioLife relative to each different Product.

1.19           “Purchase Order” means a purchase order from ORS issued to BioLife for Services.

1.20           “Quotation” means one or more written quotations executed by both parties referencing this Agreement, or otherwise attached to this Agreement and executed by both parties, which (i) identifies the Product, (ii) describes the initial  Product Specifications, (iii)  specifies the materials and components, (iv) lists the agreed upon Territories for purpose of GMP and regulatory compliance, and (v) sets the initial per unit, per Batch or other price to be paid by ORS for Manufacture and supply of Product, subject to the other terms of this Agreement.

 

1.20           “Services” means the Manufacturing and supply of Products and other services to be performed by BioLife under this Agreement.

  

2

  

 

2.           Master Agreement

2.1           Master Agreement.  This Agreement is a contractually binding master contract to permit the parties to include one or more Projects under its terms.  However, ORS is not required to engage the Services of BioLife, and BioLife is not required to provide Services to ORS, except to the extent ORS issues a Purchase Order to BioLife for Services, and BioLife accepts such Purchase Order, which will be subject to the terms and conditions of this Agreement.

2.2           Issuance of Project Quotation.  For each new Product to be supplied under this Agreement, the Parties shall execute a Quotation which shall be incorporated by reference in and made a part of this Agreement.  Except as set forth below, in the event of any conflict between the terms and conditions of a Quotation and a provision of this Agreement, the applicable provision of this Agreement shall prevail unless the Quotation expressly specifies that the particular term of the Quotation takes precedence over the terms and conditions of this Agreement in which case the Quotation shall control as to the specified provision under that particular Quotation, but not as to other provisions or other Quotations.  To the extent a Quotation has been executed by the parties prior to execution of this Agreement but is attached to this Agreement, the terms of this Agreement shall apply to such Quotation.  No Quotation shall be binding unless executed by both Parties, and may only be amended by written agreement of the parties. The initial Quotation is attached to this Agreement as Appendix B.

 

2.3           Reference to Master Agreement.  Each Purchase Order will specifically refer to this Agreement.

2.4           Conflicts.  If any provision of a Purchase Order is in direct conflict with this Agreement so that the provisions of both cannot be given effect, the terms of the Agreement shall control the specific issue to the extent of the inconsistency.  The provisions of this Agreement shall otherwise govern all contracts between BioLife and ORS to the exclusion of any other terms and conditions, including without limitation, any terms and conditions pre-printed on any purchase order, invoices and similar contractual documents used in the performance of this Agreement.  Nothing in this Agreement shall prevent ORS from engaging other contractors to provide services with respect to Product.

2.5           Financial Statements.  On or before the 45th day following the last day of each calendar quarter during the term of this Agreement, BioLife shall submit to ORS financial statements of BioLife for the immediately preceding calendar quarter.  Such financial statement shall contain a balance sheet, a statement of operations and a cash flow statement, shall be prepared in accordance with GAAP (without footnotes or customary year-end adjustments), and shall accurately and fairly display the financial condition of BioLife as of the end of each such calendar quarter.  The first such statement shall be due to ORS with respect to the calendar quarter ending March 31, 2012.

3.           Compliance and Standards

3.1           BioLife Performance.  Subject to the provisions of this Agreement, BioLife will Manufacture Product and perform the Services under this Agreement with industry standard care and skill.  Additionally, BioLife shall comply with the applicable Product Specifications, Master Batch Record, and Good Manufacturing Practices. Products Manufactured in accordance with Product Specifications and Good Manufacturing Practices are expected to meet release criteria as reasonably determined by ORS.  

3.2           ORS Performance.   ORS is responsible for providing complete and accurate Product Specifications and requirements for Manufacturing, together with additional information in the possession or control of ORS, necessary for BioLife to develop the Master Batch Records, Batch Records and other production documentation for the Manufacture of each Product.  ORS shall be responsible for all regulatory issues concerning Product submissions, listing, labeling content and end user instructions for use, and ORS shall be responsible for final Product release.

3.3           Changes.  BioLife shall promptly notify ORS in writing regarding changes to production processes, environmental changes, and similar material matters that might impact safety, Manufacturing or compliance with the Product Specifications and Good Manufacturing Practices, and shall implement such changes only after such written notice is received and approved in writing by ORS.  Conversely, ORS shall obtain BioLife’s written approval before changes are made to the Product Specifications, or other changes are made that may have a material impact on BioLife or the Manufacturing or use of the Products.  In either case, ORS and BioLife will review cost impact and adjust pricing and other terms accordingly as mutually agreed in writing by the parties.

3.4           Documentation and Reporting.  BioLife shall keep complete and maintain systematic written records of BioLife’s operations in connection with the performance of the this Agreement, and shall retain all such records for the period required by applicable law or guidelines, or for five years after completion of the Agreement, whichever is greater.  BioLife will provide ORS with the copies of each Batch Record and retain the originals for its records. All documentation and submissions to regulatory authorities in support of the Products are the responsibility of ORS except as otherwise required by law.

3.5           Master Batch Record. The parties shall mutually develop and approve a Master Batch Record for each Product (including, but not limited to Product Specifications).  Provided that all questions and requests for additional information with respect to any documentation or Product Specifications which BioLife may have are addressed by ORS, BioLife shall deliver a draft of the Master Batch Record for each Product to ORS within a reasonable period of time in order to allow ORS to review and provide input on such draft.  The Master Batch Record for each Product must be approved by both parties and, to the extent approval of both Parties is required for any changes in the Master Batch Record under this Agreement, such changes must be approved at least ten (10) days prior to commencement of Manufacturing activities with respect to the first Batch of such Product to be Manufactured using such Master Batch Record or implementing any such change, including any scheduled validation runs.

  

3

  

 

4.           Quality

4.1           Documentation. BioLife will maintain originals of the Master Batch Records and Batch Records for all Product. BioLife will provide to ORS a Certificate of Analysis and a Certificate of Compliance for all finished Product reporting, among other required items, test results and adherence to cGMP, and will provide copies of any of the foregoing as requested by ORS. The acceptance criteria for Batches will be as mutually agreed by ORS and BioLife in the Product Specification prior to commencement of any production activities. ORS is responsible for release of Product for commercial distribution.

 

All Batch Records will be held securely by BioLife for a period of at least 5 years from Manufacturing start date, or such longer period as required by law.  ORS is responsible for notifying BioLife and requesting records be maintained for greater than 5 years and contracting for ongoing storage.  All records specific to or directly supporting Product will be available for review by ORS upon request.

 

These documents include but are not limited to:

 

	
●  

	
Master Batch Records and Batch Records

 

	
●  

	
BioLife Standard Operating Procedures

 

	
●  

	
Batch Records In-process controls

 

	
●  

	
Deviation and final investigation reports

 

	
●  

	
Non-conformities and final investigation reports

 

	
●  

	
All QC records

 

	
●  

	
Certificates of Analysis and Compliance

 

	
●  

	
Raw Material Records

 

	
●

	
Validation Protocols & Reports

 

	
●  

	
Inventory records

 

	
●  

	
Calibration records

 

	
●  

	
Personnel training records

 

4.2           cGMP Compliance. The Manufacturing of Product must comply with all the requirements of the current Good Manufacturing Practices as described in FDA regulations 21 CFR Part 820 Quality System Regulation for medical devices, as amended from time to time.

 

4.3           Manufacturing, Controls and Quality Compliance. The Manufacturing will be carried out in accordance with the documentation prepared and authorized by BioLife’s Quality department and in accordance with the Manufacturing Standards.  ORS must approve all Batch Records, the Batch Master Records, Product Specifications, and Manufacturing changes prior to implementation at BioLife.  These will be treated as controlled documents and will be maintained utilizing BioLife’s document control procedure in order to ensure proper issuance and change control. BioLife will ensure and document that all personnel engaged in the Manufacture of Product shall have the education, training and experience necessary to perform assigned job functions.

 

  

4

  

 

BioLife will maintain qualified vendors, specifications, and when relevant, appropriate testing programs approved by ORS for all starting materials, reagents, intermediates, Manufacturing aids and packaging used in the scope of the Manufacturing, and all materials and components will be purchased by BioLife except as set forth in this paragraph. In the case where starting materials and components are sourced from ORS qualified vendors, appropriate acceptance criteria and corresponding analytical methods will be defined and implemented in cooperation with ORS.  BioLife shall assign unique lot numbers and track components used in each lot.  BioLife Batch history records are key documents for tracking materials used in the Manufacturing and packaging of Product.  Part numbers and lot numbers will be clearly indicated for all components.  The status of material (e.g., released, quarantined, rejected, etc.) will be clearly indicated for all Product and materials at all times.

 

BioLife will also maintain a copy of Product Specifications for ORS.  Analytical testing for which BioLife takes responsibility must be conducted at an approved vendor audited and/or approved by ORS.

 

All BioLife equipment used in the Manufacturing, controls and storage of Product for ORS and components thereof at BioLife shall be regularly calibrated/qualified according to BioLife policies and procedures.  Equipment qualification shall meet 21 CFR 820 expectations.

 

The Batches manufactured by BioLife will be tested according to testing methods and specifications approved by ORS in writing.

 

BioLife will release each Batch to ORS on basis of the Manufacturing and controls documentation review. BioLife will provide to ORS a BioLife QA-approved Batch History Record and a certificate of GMP compliance, as well as a Certificate of Analysis and Certificate of Compliance.

 

BioLife will be responsible for providing a written investigation and assessment of Product impact for any deviation during the Manufacturing of Product related specifically to BioLife facilities, equipment or aseptic process validation parameters. ORS has the right to review all documentation of Manufacturing and testing of the Product prior to authorization of shipment.  This review shall be conducted within a reasonable period of time following written notification by BioLife that the documentation is complete and ready for review.   Authorization to ship Product will be provided to BioLife in writing by the ORS QA Representative after review of the Certificates of Analysis and Compliance, Batch Record and other documentation as deemed necessary by ORS.  If ORS requests that BioLife store Product for more than 15 days after BioLife has submitted appropriate Certificates of Analysis and Compliance, the applicable Batch Record and other documents as deemed necessary by ORS for approval by ORS in compliance with this Agreement, ORS agrees to pay reasonable storage charges that will be mutually agreed to between ORS and BioLife.

 

Each Batch will be Packaged and provided to ORS with the corresponding and requested documentation.

 

All materials and Products will be Manufactured in the Facility in environments suitable for the Manufacturing stage.  BioLife will maintain environmental controls, including particulate and environmental monitoring, pest controls and housekeeping procedures in accordance with BioLife procedures and cGMP.  The use of facility supplies of water, air and part handling, etc., shall be consistent with cGMP and BioLife’s policies and procedures.

 

4.4           Change Control. Any major change to the Manufacturing or controls, including the Facility and equipment, pertaining to the process and its corresponding instructions or methods, or to the documents prepared by BioLife on behalf of ORS and detailing specific instructions together with all associated in-process controls affecting the Manufacturing or testing of processes or Product requires the written agreement of the ORS QA Representative prior to implementation.

 

4.5           Man In The Plant. ORS may, at ORS expense, place a company representative on-site at the BioLife Manufacturing facility during the Manufacture of any Product.  Such representative shall have full, unfettered access to all operations, documents, and records that pertain to the manufacture of any Product, except that access to the Grade A, Grade B, or Grade C controlled environment areas are restricted to BioLife personnel.

  

5

  

 

4.6           Material Review. All Batches for which deviations occur from the Product Specifications or procedures authorized by BioLife’s Quality department for the Manufacturing, controls, or storage of materials or Product, or any other problem arising during performance of such activities will be fully investigated by BioLife.  BioLife will immediately notify ORS (but within 24 hours in all events) in reasonable detail if BioLife determines that such an investigation is necessary or advisable.  Investigations must be completed and approved by BioLife’s Quality department. The ORS QA representative will be notified within 2 Business Days of all deviations and provided a copy of the deviation and investigation report within 12 days of BioLife’s investigation initiation.  If an investigation of any deviation, non-conformance or other failure to meet the Product Specifications takes longer than 12 days, BioLife, will provide to ORS an interim report no later than 15 days of initiation of the investigation.  If an ORS on-site representative is present, that individual will be immediately notified of deviations. ORS on-site representative shall be entitled to notify ORS QA and any other ORS personnel deemed necessary by ORS.  ORS will be included in decisions regarding Product and possible corrective actions. ORS may actively participate in any investigation described above and all results will be shared as they become available. All records of the investigation together with the rationale and justification of the decisions that are taken will be maintained with the related documentation.

Rework and reprocessing instructions and/or procedures, if possible, will be developed and approved in writing by ORS with applicable technical assistance from BioLife and provided to BioLife by ORS QA and technical staff prior to being performed by BioLife.  Written approval for all rework and reprocessing must be received from ORS QA.  All rework and reprocessing must be consistent with regulatory filings, applicable law, the Product Specifications, BioLife procedures and otherwise in accordance with this Agreement.

 

ORS provided materials found by BioLife not to be in conformance with written specifications or drawings will be clearly identified and segregated.  ORS shall be notified in writing of non-conforming materials within 48 hours of the occurrence via email and BioLife will dispose non-conforming materials according to ORS written instructions.  Any parts designated as scrap will be returned to ORS or disposed of according to ORS instructions and at ORS cost.    In case of rejections, ORS shall be responsible for the final decision to return non-conforming materials to the component or raw material supplier, if applicable.

4.7           Storage and Shipping. All materials, components, Products, work in progress and related items shall be stored and shipped per environmental requirements specified in Product  Specifications or raw material and component specifications.

4.8           Retained Samples. Samples of Product from each Batch will be retained by BioLife, as specified in this Agreement and Manufacturing instructions, and as otherwise required by law. ORS shall be entitled to designate the period for which Samples will be retained.

4.9           Samples. BioLife will pull samples for release testing, stability, retains, and research and development as instructed by the Manufacturing instructions and/or in writing by ORS. ORS will be financially responsible for any stability testing requested by ORS based on a written quote from BioLife and approved in writing in each instance by ORS. Inventory records documenting the history and purpose of removal of samples from each Batch will be maintained.

4.10           Complaints. ORS is solely responsible for all complaints. Complaints will be documented and managed in accordance with ORS procedures.  Complaints referred to BioLife for more information will be fully investigated by BioLife’s Quality department and a report prepared and issued to the ORS QA Representative within a reasonable time-frame mutually agreed to between ORS and BioLife from receipt of the complaint.

4.11           Recalls.  If either party has reason to believe that one or more Batches of a Product should be recalled or withdrawn from distribution, such party shall immediately inform the other in writing.  Recalls and withdrawals of Product shall be within the sole discretion of ORS. BioLife will cooperate fully with ORS in the event of any recall or withdrawal and will provide at ORS’s expense, such assistance in connection therewith as ORS may reasonably request.  Notwithstanding the foregoing, if any recall or withdrawal occurs as a result of Product which is determined not to be conforming to the requirements set forth in this Agreement, BioLife shall reimburse ORS for the reasonable out of pocket costs and expenses incurred by ORS in connection with such recall or withdrawal.

4.12           Regulatory Inspections. BioLife will advise ORS in writing immediately upon receipt of any notice of any regulatory inspection of BioLife that may in any way be related to the Products.  ORS shall have the right to attend any such inspection.  BioLife will provide ORS with copies of any reports or communications containing any observations arising from inspections at the facilities of BioLife carried out by any regulatory authority.  BioLife will provide ORS with a copy of all deficiencies noted and the BioLife response to the regulatory agency.  This documentation may be redacted to maintain confidentiality regarding other BioLife clients.  BioLife shall cure all deficiencies of any kind or nature noted in any regulatory inspection or audit, at BioLife’s sole cost and expense.

  

6

  

 

     4.13           Regulatory Updates. No documentation with respect to Products Manufactured by BioLife for ORS will be provided by BioLife directly to the FDA or any other regulatory authority, except as specifically agreed to in writing by ORS and BioLife or as required by law.

4.14           Audits. Subject to Section 4.5, upon reasonable advanced notice, BioLife will permit ORS, or persons designated by ORS, to audit and qualify all of the books, records, facilities and equipment related to this Agreement, and to ensure regulatory compliance of BioLife quality systems, including Manufacturing and storage facilities, Manufacturing and related procedures used by BioLife to Manufacture, inspect, package, label or store Product and constituent materials.  Audits may also be requested by ORS for ORS customers.  ORS QA representative shall arrange with BioLife for such audits and accompany any customers during the BioLife audit.

ORS is responsible for auditing vendors (raw material, analytical laboratory, etc.) named in Manufacturing documents and the Product Specifications other than those contracted by BioLife.  Those vendors and analytical laboratories used by BioLife must be certified and included on the BioLife list of approved suppliers according to BioLife procedures.  BioLife will share with ORS the approved supplier list for ORS raw materials and services.

4.15           Materials.  Except as otherwise provided in this Agreement, BioLife acknowledges and agrees that it will provide all materials and components, and equipment, necessary to Manufacture Product in accordance with this Agreement.  BioLife agrees not to provide or use any such materials for any third party, and to handle and store all such materials in compliance with cGMP and other sound industry practices and in compliance with applicable law.

4.16  EU Qualified Person.  If applicable laws require that a “Qualified Person”, as defined in the applicable European Union regulations (the “Qualified Person”) release Product, then ORS shall appoint a Qualified Person in compliance with applicable EU regulations, and such Qualified Person shall be responsible for the release of Product within the applicable territory, and shall fully comply with applicable EU laws, regulations and guidance, provided that BioLife shall continue to be responsible for release testing and issuance to ORS of the Certificate of Analysis and Certificate of Compliance, and all other obligations of BioLife under this Agreement.

4.17  Media Fill/Line Validation. BioLife shall conduct process simulations (“Media Fills”) in accordance with ISO 13408-1:2008, Aseptic Processing of Health Care Products, Part 1, General Requirements (and subsequent amendments) prior to manufacturing the first lot of Product.  As required by ISO 13408-1:2008, scheduled process simulation requalification shall be conducted twice annually (approximately every six months) for each aseptic process and filling line.   BioLife will perform Media Fills according to Master Batch Records approved by ORS in writing.  ORS shall assume all financial responsibility for process simulations related to the Manufacturing process for ORS Products, which shall include materials used and time required to perform Media Fill, based on a written quote from BioLife and approved in writing in each instance by ORS.

  

7

  

5.           Forecasts, Orders and Deliveries

5.1           Forecast and Raw Materials.  ORS shall provide BioLife with a 12-month rolling forecast of Product deliveries that will allow BioLife to order, receive and approve raw materials prior to the issuance of a Purchase Order.  The initial 12 month rolling forecast accepted by BioLife is included in Appendix A to this Agreement. ORS will be financially responsible for any raw materials ordered by BioLife to produce up to six (6) months of Product deliveries from this 12 month rolling forecast.  Upon written request by BioLife, the six (6) month limit set forth in the preceding sentence may be extended by ORS in writing on specific materials.  ORS shall update and deliver to BioLife the 12-month rolling forecast by no later than the last day of each fiscal quarter. Should ORS fail to provide an updated 12 month forecast, the previous forecast shall remain effective.

Increases to the rolling forecast of more than 500 liters in any 90 day period from the most recent forecasted quantity for such 90 day period must be approved in writing by BioLife.  BioLife and ORS agree that Product shipments may commence as early as both parties agree, and in any case, before March 2012 if possible.

5.2           Purchase Orders.  ORS shall provide Purchase Orders to cover calendar quarters of deliveries.  All Purchase Orders shall be sent by first class mail, email or facsimile. ORS shall issue Purchase Orders to BioLife for Product production lots at least 60 days prior to the beginning of the next calendar quarter provided that the requirements stated in Section 5.1 are met.  Within 5 Business Days after BioLife’s receipt of a Purchase Order, BioLife shall either accept the Purchase Order or provide a written explanation for rejection, or a new proposed delivery date.

5.3           Minimum Purchase Order Quantities.  ORS agrees to place Purchase Orders for at least 80% of the quantities listed in Appendix A.

5.4           Shipping.  All shipments are FCA BioLife (per INCOTERMS 2010). BioLife shall ship Products to the address set forth as specified in the Purchase Order.

5.5           Raw Materials.  In order to insure an adequate inventory of raw materials for BioLife Manufacturing of Products, ORS may, at its discretion, purchase additional lots of raw materials and provide same to BioLife at the Facilities.  These additional lots of raw materials would be rotated into BioLife’s raw material inventory and, once so used by BioLife would be replaced in the same quantity and type by BioLife in such time as to ensure a continuing appropriate supply of raw materials.

6.           Scheduling, Manufacturing Ramp Up and Equipment Purchased by ORS

6.1           BioLife Scheduling Policy.  To maintain a smooth manufacturing schedule, to offer reasonable flexibility to ORS, and to allow the BioLife project managers to provide ORS with estimated filling dates for the purposes of completing a timeline, the following scheduling policy shall apply to this Agreement.  The BioLife manufacturing division will set BioLife’s manufacturing schedule, and only those projects that have achieved the following project milestones will be confirmed on the schedule:

 

(a)           Receipt of signed Agreement, and an accepted Purchase Order;

 

(b)           All required validations/qualifications/engineering runs are performed and approved;

 

(c)           Production Batch record approved by ORS and BioLife;

 

(d)           All equipment and preparation items in-house and available for use;

 

(e)           Components, excipients and/or active ingredients have been received and released.

 

Once on the manufacturing schedule, ORS will be notified of the actual fill date.  A postponement or cancellation caused by ORS will incur fees as described below.  BioLife will work closely with ORS to achieve ORS’s scheduling requirements.  BioLife’s manufacturing schedule is necessarily complex, and BioLife reserves the right to change the schedule to permit maximum utilization of the facility.  Should scheduling changes be necessary, BioLife shall notify ORS and in no event shall BioLife’s actual production date be greater than 15 days from the original production date accepted by BioLife.

 

6.3           Equipment Purchased by ORS. BioLife agrees not to use equipment purchased by ORS for any purpose other than the Manufacture ORS Products.

 

6.4           Exclusivity.  During the term of this Agreement and for a period of two (2) years following the termination or expiration of this Agreement, BioLife agrees that it will not directly or indirectly manufacture, produce, promote, process or sell, for its own account or on behalf of any third party, any solution that is approved for clinical use in the perfusion, flushing, irrigation or static storage of human organs (including for this purpose, to the best of BioLife’s knowledge pancreatic islet cells) that are harvested, transported or otherwise made ready for transplant.

 

  

8

  

 

7.           Pricing, Payment Terms

 

7.1           Pricing.  The initial prices for the Services shall be as set forth on Appendix B.

7.2           Annual Price Review.  The parties agree to review and, if appropriate, to adjust pricing in twelve-month intervals during the term of this Agreement.  The prices shall be quoted and paid in United States Dollars.

7.2           Price Increases for Raw Materials and Components.  The parties agree to review and adjust pricing if any raw material cost increases by more than 10%.

 

 

7.3           Invoicing.  BioLife will submit invoices to ORS upon the issuance of the completed Batch Record which complies fully with this Agreement for each Batch.  All invoices shall be sent by first class mail, email or facsimile.

7.4           Payment.  ORS shall pay all amounts correctly invoiced by BioLife within 30 days after the date of such invoice.  ORS shall pay a late fee, commencing on the due date, on all delinquent payments.  The late fee shall be the lesser of 1.0% per month (12% per annum) or the maximum rate allowed under applicable law.  Without limiting any other remedies, BioLife may withhold future deliveries if payment is not received in a timely manner.

 

7.5           Taxes.  All prices for any Products are exclusive of any export, foreign import, federal, state or local tax or excise.  Any such tax or excise paid by BioLife (other than taxes on BioLife’s income) shall be reimbursed by ORS, and shall appear as a separate item on the BioLife invoice; provided, however, that BioLife shall not pay any such tax or excise if BioLife receives a valid tax exemption certificate from ORS prior to shipment.

8.           Acceptance

8.1.           Time to Examine Shipment.  Following delivery of a shipment of Products to ORS’s premises, and during the time Products are located at ORS’s premises, ORS will have a period of 10 days in which to examine the quantities of Products delivered: (i) for substantial conformity with the Purchase Order, and (ii) to ensure that such delivery of Products is accompanied by a Certificate of Analysis, and (iii) visually inspecting the exterior of the shipment of Products to verify that the shipment appears to be in good condition. If ORS determines that the shipment does not pass such examination it shall promptly notify rejection of the shipment to BioLife in writing.

8.2.           Returns.  Within 10 days of receipt by BioLife of a notice of rejection from ORS in accordance with Section 8.1, BioLife shall issue a return authorization in writing to ORS.  In the event that a return authorization is so issued, ORS shall package and return to BioLife the quantity of Products in question at BioLife’s expense and BioLife shall replace such quantity within a commercially reasonable amount of time mutually agreed upon by ORS and BioLife.  If the payment in respect of such quantity of Products is outstanding, the payment date shall be postponed until 30 days from the date such replacement quantities are received and accepted by ORS in accordance with this Section 8.

8.3.           Dispute resolution.  After BioLife receives a rejection notice from ORS pursuant to Section 8.1 and BioLife issues a return authorization under Section 8.2, BioLife shall analyze any quantity of Products rejected by ORS for non-conformity with the requirements of Section 8.1 within 10 days of receipt of such returned Products and present its findings with respect to such quantity of Products to ORS.  If such tests confirm non-conformity with the relevant Specification, BioLife shall promptly, at ORS’s option and at BioLife’s cost and expense either: (i) supply a conforming quantity of Products in the same quantity as the rejected Products and reimburse ORS for any shipping charges in relation to such non-conforming quantity of Products as specified in this Section 8.2 or (ii) refund the purchase price of the rejected Products, inclusive of any shipping charges.  If the quantity of confirmed non-conforming Product is less than 200 units, BioLife shall increase the quantity of the next Purchase Order placed by ORS by the quantity of non-conforming Product, at no additional cost to ORS.  If the quantity of non-conforming Product is greater than 200 units, BioLife shall use its best efforts to manufacture replacement Product at an expedited rate, resulting in delivery of such replacement Product no later than six (6) weeks from the date of notification by BioLife of determination of a Product as non-conforming.  If the Parties cannot agree on whether the quantity of Products in question conform to the requirements of Section 8.1 an independent qualified laboratory reasonably acceptable to both Parties, and at a cost shared equally by both Parties, shall analyze both ORS’s and BioLife’s samples of the Products in question, and the definitive results of such laboratory shall be binding on the Parties.  If the quantity of Products in question is determined to be non-conforming, such non-conforming Products shall be held for BioLife’s disposition, or shall be returned to BioLife, in each case at BioLife’s expense, as directed by BioLife no later than 10 days following such determination.  If the quantity of Products in question is determined to be conforming and provided that the Certificate of Analysis and Certificate of Compliance accompanying such quantity of Products did not indicate it to be non-conforming, such quantity of Products shall be returned to ORS at ORS’s cost and expense, including any associated testing costs.

  

9

  

 

9.           Limited Warranties

9.1           BioLife Warranty.  BioLife represents and warrants that (i) Products manufactured by BioLife for ORS will conform to the Product Specifications and Master Batch Records, and will have been Manufactured in accordance with the Manufacturing Standards and applicable laws, rules and regulations, (ii) BioLife’s use of any of its Intellectual Property will not infringe or misappropriate the Intellectual Property of any third party, (iii) BioLife has obtained and at all times shall maintain, at its sole cost and expense, all non-Product specific licenses, permits, certifications and approvals required under applicable law for its Facility and to Manufacture Product at the Facility, (iv) as of the date of this Agreement and continuously during the term of this Agreement that neither it nor, to the best of its knowledge any of its employees or agents performing Services has been (a) debarred or (b) convicted of a crime for which a person can be debarred, under Section 335(a) or 335(b) of the Federal Food, Drug, and Cosmetic Act (the “Act”), (v) it has never been and, to the best of its knowledge, none of its employees or agents has ever been (a) threatened to be debarred under the Act or (b) indicted for a crime or otherwise engaged in conduct for which a person can be debarred under the Act, and (vi) the execution, delivery and performance of this Agreement by it does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, and does not violate any law or regulation of any court, governmental body or other administrative authority having authority over it.  BioLife agrees that it shall promptly notify ORS in writing in the event it receives notification of any such debarment, conviction, threat or indictment.  BioLife does not warrant the function of Products Manufactured by BioLife for ORS, and BioLife makes no representations or warranties regarding the effectiveness of the Products for any purpose whatsoever.  EXCEPT AS EXPRESSLY SET FORTH IN THIS SECTION 8, BIOLIFE SPECIFICALLY DISCLAIMS, ALL REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, REGARDING THE PRODUCTS AND SERVICES CONTEMPLATED BY THIS AGREEMENT, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT.

10.           Liability

10.1           Acknowledgment.  ORS acknowledges that BioLife has quoted its fees in reliance upon the limitations on liability described in this Section 9.

10.2           Finished Product Limitation.   BioLife’s liability for finished Product shall be limited to sterility based on documented filter validation from ORS, or a waiver to use the specified filter signed by ORS.  The liability arising therefrom will be limited to production sufficient to replace any affected Product.

10.3           Indemnification.  ORS shall indemnify, defend and hold BioLife and its officers, directors and employees and successors harmless from any claim, damage, loss, costs and liability, including reasonable attorney’s fees (collectively, “Losses”), incurred by or made against BioLife or any such other person arising from or relating in any way to (i) any claim asserted with respect to any use of ORS’s Products, (ii) a claim by a third party that ORS intellectual property applicable to the Product infringes or misappropriates said third party’s intellectual property rights, except to the extent of any Losses arising from a failure of BioLife to adhere to the Product Specifications, or (iii) a violation of any law, rule or regulation applicable to ORS’s obligations under this Agreement; provided, however, that the foregoing indemnification shall not apply to any claim or Losses that result from a breach of this Agreement by BioLife or the gross negligence or willful misconduct of ORS.

BioLife shall indemnify, defend and hold ORS and its officers, directors and employees and successors harmless from any Losses incurred by or made against ORS or any such other person arising from or relating in any way to (i) the gross negligence or willful misconduct of BioLife or any employee, officer or director of, or contractor to, BioLife; (ii) a claim by a third party that BioLife’s use of any BioLife Intellectual Property independent of Product infringes or misappropriates such third party’s intellectual property rights; (iii) any violation of any law, rule or regulation applicable to BioLife’s obligations under this Agreement; or (iv) any breach of this Agreement by BioLife, provided, however, that the foregoing indemnification shall not apply to the extent such Losses result from the gross negligence or willful misconduct of ORS.

10.4           General Limitation.  Without limiting the foregoing provisions of this Section 10, except with respect to BioLife’s indemnification obligation in Section 10.3 above, in no event will BioLife’s total liability to ORS exceed the amounts invoiced by and paid to BioLife for the relevant Products, on a lot specific basis.  Additionally, even if BioLife has been advised of the possibility of such damages, UNDER NO CIRCUMSTANCES WILL BIOLIFE BE LIABLE TO ORS UNDER ANY THEORY FOR ANY INCIDENTAL, CONSEQUENTIAL OR SPECIAL DAMAGES ARISING FROM ANY LOSS RELATING TO THE SUBJECT MATTER OF THIS AGREEMENT, SUCH AS BUT NOT LIMITED TO, LOSS OF REVENUE, LOST PROFITS OR LOST BUSINESS, except in the case of BioLife’s indemnification obligation set forth in Section 10.3 above or a breach by BioLife of any confidentiality obligation owing to ORS.

10.4           Insurance.  During the term of this Agreement and for a period one year thereafter, BioLife and ORS shall each carry Commercial General Liability Insurance, combined single limit, including without limitation, Product Liability and, in the case of ORS, Product Liability coverage.  The insurance shall cover amounts not less than two million dollars ($2,000,000) for each occurrence and in the aggregate.

  

10

  

11.           Intellectual Property and Other Property Rights

11.1           Confidentiality.  All Confidential Information disclosed by either party to the other under this Agreement shall be subject to the Mutual Nondisclosure Agreement signed by BioLife and ORS, dated effective September 8, 2011, which agreement shall remain in full force and effect in accordance with its terms and shall be extended and in effect for the duration of this Agreement and for a period of seven (7) years thereafter.

11.2           Limited License.  Subject to the provisions of this Agreement, ORS hereby grants to BioLife a non-transferable, non-exclusive license (without rights to sublicense) under ORS’s Intellectual Property covering the Products solely to the extent necessary for BioLife to perform its obligations under this Agreement.  No implied rights or licenses relating to any ORS Intellectual Property are granted under this Agreement and ORS expressly reserves all rights in and to its Intellectual Property.

                11.3           Title and Ownership of Materials. ORS shall remain the sole owner of all right, title and interest to any and all materials, documents and equipment supplied or provided to BioLife by ORS (including without limitation the Product Specifications), or otherwise relating to the Product (and not to the Manufacture of Product) and any and all materials purchased by ORS or by BioLife specifically for ORS’s benefit, evidenced by a confirming order, which is paid by ORS.  BioLife shall remain the sole owner of all right, title and interest to any and all materials purchased by BioLife not specifically for ORS’s benefit, not evidenced by a confirming purchase order, or not paid for by ORS.  All ORS material in the possession of BioLife shall be maintained in designated, segregated locations, as reasonably determined by BioLife.  

With respect to Products Manufactured by BioLife for ORS, all discoveries, inventions, know-how, developments, methods, techniques, trade secrets, innovations, updates, modifications, enhancements, improvements, copyrights, data, documentation, specifications and other intellectual property of any kind, whether or not protectable under patent, trademark, copyright or similar laws, that is created during the term of this Agreement by BioLife, or by ORS and BioLife jointly, shall be and remain the sole and exclusive property of ORS, and BioLife agrees to executed and deliver all documents and instruments as ORS may request, at the cost and expense of ORS, to secure title to any such items to ORS. This does not include discoveries, inventions, know-how, developments, methods, techniques, trade secrets, innovations, updates, modifications, enhancements, improvements, copyrights, data, documentation, specifications and other intellectual property of any kind, whether or not protectable under patent, trademark, copyright or similar laws, that is created during the term of this Agreement by BioLife which are not specifically related to the Products Manufactured by BioLife for ORS.

12.           Term and Termination

12.1           Term.  This Agreement shall be effective as of the Effective Date and shall continue in force for three years, unless earlier terminated as provided in this Section 12.   This Agreement shall automatically renew for successive one year terms unless either Party provides at least 180 days prior notice of its desire to terminate.

12.2           Default.  If either party defaults in the performance of any of its material obligations under this Agreement, and does not cure such default within 30 days after written notice, then the non-defaulting party, at its option, may terminate this Agreement by giving written notice of termination to the defaulting party.

12.3           Voluntary Termination. Either party may terminate this Agreement at any time, without cause, upon 180 days prior written notice.

12.4           Effect of Termination. At the election of ORS, BioLife agrees that it will finish the Manufacture of any Batch in process at the time of termination or expiration of this Agreement, subject to the continuing terms and conditions of this Agreement with respect to any such Batch.  ORS shall remain liable for all undisputed payments due and owing to BioLife as of the date of termination or expiration, including without limitation any continuing Manufacturing by BioLife pursuant to the preceding sentence.

12.4           Insolvency.  This Agreement may be terminated by either party, upon written notice, (a) upon the institution of receivership or bankruptcy proceedings that are not dismissed within 60 days thereafter, or (b) upon the other party’s dissolution or ceasing to conduct business in the normal course.

12.5           Return of Property.  Within a reasonable time after the effective date of the termination of this Agreement, BioLife shall deliver to ORS all ORS materials, data, and information.  ORS shall be responsible to instruct BioLife where to ship items and ORS shall be responsible to pay the costs of shipping such items.  If ORS fails to pickup, pay for or accept delivery of its materials within a reasonable time after termination of the Agreement, ORS shall be responsible to pay BioLife for the cost of storing the materials; provided, however, that BioLife shall not have any obligation to store the materials and may dispose of the materials in any manner permitted by applicable law.

 

12.6           Remedies.  Compliance with this Section 12 does not limit or waive either party’s potential remedies for a breach of this Agreement.  Termination of this Agreement shall not release either party from any obligation or right that accrued to that party prior to the effective date of termination or which later accrues from an act or omission, which occurred prior to the effective date of termination.

 

12.7           Survival.  In addition to the other provisions of this Agreement explicitly stated to survive termination of this Agreement, Sections 8.0, 9.0, 10.0, 11.0, this Section 12.0 and Section 13 shall survive such termination or expiration in accordance with their terms.

 

  

11

  

 

13.           General Provisions

13.1           Governing Law and Venue.  This Agreement shall be governed by and interpreted in accordance with the laws of the State of Washington, without reference to its conflict of laws provisions.  Any legal proceeding that relates in any way to this Agreement shall be subject to the exclusive jurisdiction of the federal and state courts in the County of King, state of Washington.

13.2           Partial Invalidity.  If any provision in this Agreement is be held by a court of competent jurisdiction to be invalid or unenforceable, that provision shall be severed from the remainder of this Agreement, and the remaining provisions shall remain in full force and effect.

13.3           Relationship of the Parties.  BioLife and ORS are independent contractors under this Agreement.  Nothing contained in this Agreement is intended nor is it to be construed so as to constitute BioLife and ORS as partners or joint venturers with respect to this Agreement.   Neither party has the power or right to bind or obligate the other party.

13.4           Modification.  No alteration, amendment, waiver, cancellation or any other change in any term or condition of this Agreement shall be valid or binding on any party unless the same shall have been mutually agreed in writing by both parties.

13.5           Waiver.  The failure of any party to enforce at any time any of the provisions of this Agreement, or the failure to require at any time performance by the other parties of any of the provisions of this Agreement, shall in no way be construed to be a present or future waiver of such provisions, nor in any way affect the right of any party to enforce each and every such provision thereafter.  The express waiver by any party of any provision, condition or requirement of this Agreement shall not constitute a waiver of any further obligation to comply with such provision, condition or requirement.

13.6           Assignment.  BioLife may not assign this Agreement, or any of its rights or obligations (by operation of law or otherwise) hereunder, without the prior written consent of ORS granted or withheld in the discretion of ORS.  Any change of more than 25% of the ownership of BioLife shall be deemed an assignment for purposes of this Section 13.6, and BioLife shall immediately notify ORS of each such change.  Subject to the foregoing, this Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.

13.7           Notices.  All notices required to be given under this Agreement can initially be made via email but must also be made in writing and delivered (a) two days after deposit with regularly scheduled commercial delivery service, Federal Express or equivalent; or (b) on the date of personal delivery to an officer or authorized representative.  Notices mailed or sent by commercial delivery shall be made to the addresses stated at the signatures to this Agreement.  Any party may change its address for notice by written notice given in accordance with the foregoing requirements.  Despite the foregoing, actual receipt of written notice shall constitute notice on the date received.

13.8           Force Majeure.  Notwithstanding anything else in this Agreement, no default, delay or failure to perform on the part of any party shall be considered a breach of this Agreement if such default, delay or failure to perform is shown to be due to causes beyond the reasonable control of the party charged with a default, including, but not limited to, causes such as strikes, lockouts or other labor disputes, riots, civil disturbances, actions or inaction’s of governmental authorities or suppliers, epidemics, war, terrorist attacks, embargoes, severe weather, fire, earthquakes or other acts of God; provided, that for the duration of such force majeure the party charged with such default must continue to use all reasonable efforts to overcome such force majeure event.

13.9           Dispute Resolution.  In the event of any disagreement with respect to this Agreement, the matter shall be referred to one corporate officer of each party.  The officers shall negotiate in good faith to resolve the dispute within 30 days.  If the negotiations do not result in a mutually satisfactory resolution of the issue in question, then the matter shall be resolved by any procedure agreed to by such individuals or, in the absence of such an agreed procedure, in court.  Notwithstanding the foregoing, in no event will either party be obligated to consult with the other party prior to seeking any equitable remedies it may have.

  

12

  

 

13.10           Entire Agreement.  The provisions contained in this Agreement and the NDA constitute the entire agreement between the parties and supersede all previous agreements and understandings, whether oral or written, between the parties hereto with respect to the subject matter hereof and thereof.

13.11           Export Controls.  The parties shall comply with all applicable laws, regulations and restrictions of the United States concerning the export of products, technical data and direct products thereof including, with­out limitation, all regulations regarding export, asset control and destination control of the Commerce, Treasury, State and Defense Depart­ments of the United States Government, and the Export Administration Act of 1979, as amended from time to time.

13.12           Third Party Beneficiaries.  This Agreement is made solely for the benefit of BioLife and ORS, and their respective successors and permitted assigns.  Nothing in this Agreement is intended to confer any rights or remedies under or by reason of this Agreement on any others.

13.13           Headings.  Headings used in this Agreement are for convenience only and will not be used to construe or interpret this Agreement by either party.

13.14           No Use of Name.  BioLife, on behalf of itself and its employees, agents and affiliates, agrees not to use the name of ORS or any of its employees, agents or affiliates, or reference any of their Products, in any publicity, advertising or other publication (other than required filings with the Securities and Exchange Commission, excluding prices, commercial terms or volumes, which are and remain the Confidential Information of ORS) or as otherwise required by any governmental authority, without ORS’s prior written approval granted or withheld in ORS’s sole discretion.

 

	 	BIOLIFE SOLUTIONS, INC.:	 	 	ORGAN RECOVERY SYSTEMS, INC.:	 
	 	 	 	 	 	 
	 By:	
/s/ Michael Rice  

	 	 By:	
/s/ David Kravitz

	 
	 	
Michael Rice  

	 	 	
David Kravitz

	 
	 	
Chief Executive Officer

	 	 	
Chief Executive Officer

	 

 

 

 

  

13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]